Bristol-Myers Paying $10 Million to Exit HIV Drug Antitrust Case

Bristol-Myers Squibb Co. has reached a $10 million settlement of antitrust claims over its alleged role in a scheme to delay generic versions of Gilead Sciences Inc.'s blockbuster HIV drugs, according to a federal court filing in San Francisco.

The pension funds leading the case sought preliminary approval for the agreement from Judge Edward M. Chen, who’s presiding over the proposed class action consolidated in the U.S. District Court for the Northern District of California on behalf of “end payers” like insurers.

The deal “achieves nearly everything that remains in the litigation for these plaintiffs to achieve against BMS,” they ...